Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS) will report fourth quarter and full year 2025 financial results and provide business updates on March 24, 2026 at 4:30 p.m. ET. A live webcast and presentation will be available in the company’s Events section at http://ir.fractyl.com and archived for replay after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – GUTS
In the Mar 17 session, GUTS declined 0.20%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.7% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Clinical milestone | Positive | -6.2% | Completion of REMAIN-1 pivotal cohort randomization and timeline to FDA filing. |
| Jan 29 | Clinical data | Positive | -68.0% | Positive 6-month REMAIN-1 midpoint data with favorable weight maintenance signals. |
| Jan 06 | Management change | Neutral | -2.9% | Appointment of new CFO to support commercial-stage preparedness. |
| Jan 05 | Strategic roadmap | Positive | -8.4% | 2026 clinical and regulatory roadmap with reported cash position and key milestones. |
| Dec 15 | Warrant call | Positive | -3.6% | Call of Tranche A warrants tied to earlier clinical success and trading milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including positive clinical and strategic updates, has often been followed by negative next-day price reactions.
Over the last six months, GUTS has issued multiple clinically and strategically important updates, yet short-term price reactions were mostly negative. Positive REMAIN‑1 midpoint data, completion of pivotal cohort randomization, and a 2026 roadmap with cash of $85.6 million all saw next‑day declines. Even warrant call terms tied to prior trading strength and senior leadership changes were followed by modest pullbacks. Today’s earnings date announcement fits into a backdrop where fundamentally constructive news has not translated into immediate price strength.
Key Terms
type 2 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
